Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × ALK-positive NSCLC × brigatinib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 Lung Neoplasms 3 Carcinoma 3 Lymphoma, Large-Cell, Anaplastic 2 Carcinoma, Squamous Cell 2 Carcinoma, Large Cell 2 Adenocarcinoma 2 ALK-positive Advanced NSCLC 2 Neoplasms 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1

Interventions

Crizotinib 2 lorlatinib 1 ceritinib 1 brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

549 enrolled 28 charts

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡